Cost paramount when choosing metastatic breast cancer treatment
“Our analysis provides quantifiable evidence to help providers choose lower priced, but equally effective sequences of drugs.”
Genetic tests create treatment opportunities and confusion for breast cancer patients
Patients are sometimes left paying out-of-pocket for exams that are not yet the standard of care, and even the most up-to-date oncologists may be...
A farewell to arms? Drug approvals based on single-arm trials can be flawed
Objective responses, not time-dependent survival outcomes, should be endpoints for single-arm trials, with results only used for conditional...
Time to cancer diagnoses in U.S. averages 5 months
Diagnosis time varied significantly across tumor types, as well as within the same tumor type.
Clinical Topics & News
Single Institution Retrospective Review of Patterns of Care and Disease Presentation in Female Veterans With Breast Cancer During the COVID-19 Pandemic
Sex is still a taboo subject for patients with breast cancer
Only one out of four patients considered consulting a sexologist.
Time to pull back on postsurgery radiation in breast cancer?
Prospective Dutch study suggests no harm in de-escalating therapy in cT1-2N1 patients.
Tumor-bed radiotherapy boost reduces DCIS recurrence risk
Regardless of the whole breast irradiation fractionation schedule, a 16 Gy tumor-bed boost halved the risk of DCIS recurrence at 5 years.
In denial: When patients don’t want to believe they have cancer
“It appears there is a paucity of answers sadly.”
‘Flat denial’ can leave breast cancer patients with lasting scars
“I’ll just leave a little extra skin, in case you change your mind.”